Skip to Content

17th Annual Meeting Collaborative Group of the Americas on Inherited Colorectal Cancer

October 7–8, 2013


Hilton Anaheim

777 West Convention Way

Anaheim, California

 

General Information

  • Conference Brochure
  • Conference Agenda
  • Committee and Speaker
  • Registration Information
  • Hotel and Transportation
  • Call for Abstracts and Scholar Award Information
  • Anaheim Visitor Information

Goal

Colorectal cancer is one of the most common and preventable cancers affecting American men and women today. As new information and cutting edge approaches to cancer care emerge, it is critical to educate and support the health professionals who apply and evaluate these constant updates to clinical practice. The conference is structured to accomplish this monumental task, gathering health care professionals who care for individuals who have or are at high risk for colorectal cancer and their families. Topics highlight the importance of screening and surveillance, evidence based approaches to new diagnostic techniques, devices, and pharmaceuticals, limitations of current technology, and barriers to the diagnosis and prevention
of cancer. Through the use of patient centered decision support tools, the audience will gain experience with current technologies that enhance their ability to diagnose hereditary colon cancer. Genetic, surgical, and pathologic approaches to the diagnosis and management of individuals with hereditary colon cancer are integral to the conference as well.

Educational Objectives

After attending the conference, participants should be able to

  • Compare and contrast new genomic testing technologies and prepare to use them effectively in clinical practice (Knowledge, Competence);
  • Identify clinical decision support tools that can aid in the identification of patients with hereditary colorectal cancer symdromes (Knowledge);
  • Comprehend and implement universal endometrial cancer screening methods for Lynch syndrome to improve patient outcomes (Knowledge, Competence, Performance, Patient Outcomes);
  • Apply strategies for increasing the uptake of genetic testing and surveillance for hereditary colorectal cancer among ethnic minorities (Knowledge, Competence, Performance);
  • Use analytical tools and case examples to provide an appropriate assessment of variants of uncertain significance (VUS) identified through genetic testing (Knowledge, Competence, Performance);
  • Properly apply evidence-based cancer screening and prevention tools in patients with hereditary colorectal cancer syndromes (Knowledge, Competence, Performance, Patient Outcomes);
  • Develop a diagnostic or management approach for patients who present with atypical hereditary colorectal cancer syndromes (Knowledge, Competence).

Target Audience

This conference will be directed to colorectal and other surgeons, medical oncologists, gastroenterologists, cancer researchers, registry coordinators, genetic counselors, and geneticists, psychologists and other professionals involved in hereditary colorectal cancer.

Educational Methods

Lectures – Panel Discussions – Questions and Answers – Case Studies – Poster Session

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status.  Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Physician Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center
and The Collaborative Group of the Americas.  The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 13.50 AMA PRA Category 1 Credits™.  Physicians should claim only credit commensurate with the extent of their participation in the activity.

Ethics Credit

The presentation, Ethical/Legal/Social Issues has been designated by The University of Texas MD Anderson Cancer Center for 0.25 AMA PRS/PRA Category 1 Credits™ in medical ethics and/or professional responsibility.

Genetic Counselor CEU’s

This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

The National Society of Genetic Counselors (NSGC) has authorized The University of Texas MD Anderson Cancer Center to offer up to 1.558 CEUs or 15.58 contact hours (Category 1) for the 17th Annual Meeting – Collaborative Group of the Americas on Inherited Colorectal Cancer.  The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of certification and recertification.

  • There is a $25 fee for claiming CEUs.  If you are a CGA member, the $25 fee will be covered.  If you are not a CGA member, you will need to bring a check for $25 made out to NSGC.  This needs to be turned in at the registration desk with the CEU Verification Form.

CME Certificates and Attendance Verification Certificates

Certificates awarding AMA PRA Category 1 Credits™ or certificates documenting attendance will be distributed to participants as they depart the symposium.  To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.


© 2014 The University of Texas MD Anderson Cancer Center